About two months after announcing that it was reducing its workforce by 45% and focusing on two core R&D programs, Rallybio Corp. has gotten support from pharma giant Johnson & Johnson for its efforts to develop a therapy to prevent a rare disease that can cause uncontrolled bleeding in fetuses and infants. J&J has nipocalimab in Phase III to treat the disorder – fetal and neonatal alloimmune thrombocytopenia (FNAIT) – so the companies decided to make their efforts complementary while stopping short of a co-development arrangement.
Odd Coupling: J&J, RallyBio Collaborate As Only Firms Focused On FNAIT
While not co-developing each other’s drugs, J&J and financially troubled RallyBio are working on complementary approaches to the rare disease fetal and neonatal alloimmune thrombocytopenia.
More from Rare Diseases
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.